Formulary Watch |

All News - Page 21

Specialty Drugs Driving Increase in Hospital Pharmacy Spend
Specialty Drugs Driving Increase in Hospital Pharmacy Spend
Specialty Drugs Driving Increase in Hospital Pharmacy Spend
August 23, 2023
Carina Dolan, Pharm.D., talks about the trends that are driving both the acute and non-acute spending in hospitals for the next year.
FDA Grants Priority Review to Xtandi for Earlier Treatment in Prostate Cancer
FDA Grants Priority Review to Xtandi for Earlier Treatment in Prostate Cancer
FDA Grants Priority Review to Xtandi for Earlier Treatment in Prostate Cancer
August 23, 2023
If approved, Xtandi would be the first hormonal therapy for non-metastatic patients with increasing PSA levels. The FDA has assigned an action date in the quarter of 2023.
FDA Sets Review Date for First-in-Class Therapy for MDS
FDA Sets Review Date for First-in-Class Therapy for MDS
FDA Sets Review Date for First-in-Class Therapy for MDS
August 22, 2023
The FDA set an action date of June 16, 2024, for imetelstat to treat transfusion-dependent anemia in myelodysplastic syndromes. Regulators said they plan to hold an advisory committee meeting as part of their review.
FDA Approves Abrysvo to Prevent RSV in Infants
FDA Approves Abrysvo to Prevent RSV in Infants
FDA Approves Abrysvo to Prevent RSV in Infants
August 22, 2023
Abrysvo is the first RSV vaccine approved to be given to pregnant women at 32 to 36 weeks to prevent infection in infants.
FDA Approves Ingrezza for Disorder Associated with Huntington’s Disease
FDA Approves Ingrezza for Disorder Associated with Huntington’s Disease
FDA Approves Ingrezza for Disorder Associated with Huntington’s Disease
August 21, 2023
In addition to tardive dyskinesia, Ingrezza now also treats chorea associated with Huntington’s disease, which is a movement disorder that effects coordination, gait, swallowing and speech.
FDA Approves Higher Dose Eylea
FDA Approves Higher Dose Eylea
FDA Approves Higher Dose Eylea
August 21, 2023
The higher dose of Eylea allows longer intervals between injections for patients with macular degeneration and diabetic retinopathy. It will have a list price of $2,625 per single-use vial.
FDA Approves Veopoz for Hereditary Immune Disease
FDA Approves Veopoz for Hereditary Immune Disease
FDA Approves Veopoz for Hereditary Immune Disease
August 21, 2023
Veopoz is the first treatment for CHAPLE disease, which causes damage to blood and lymph vessels along the upper digestive tract. The list price is $34,615.38 per single-use vial.
FDA Sets PDUFA Date for Full Approval of Tarpeyo
FDA Sets PDUFA Date for Full Approval of Tarpeyo
FDA Sets PDUFA Date for Full Approval of Tarpeyo
August 18, 2023
The FDA granted accelerated approval to Tarpeyo in December 2021 to treat patients with primary IgA nephropathy, a rare disease that attacks the kidneys. The action date for full approval is Dec. 20, 2023.
Blue Shield of California to Work with Prime Therapeutics to Negotiate Drug Prices
Blue Shield of California to Work with Prime Therapeutics to Negotiate Drug Prices
Blue Shield of California to Work with Prime Therapeutics to Negotiate Drug Prices
August 18, 2023
Blue Shield’s new program will unbundle pharmacy services for increased transparency with the goal of saving $500 million annually. The health plan is also teaming up Mark Cuban Cost Plus Drug Company and Amazon Pharmacy.
Shifting Health Plan Policies Impact Access to Specialty Drugs
Shifting Health Plan Policies Impact Access to Specialty Drugs
Shifting Health Plan Policies Impact Access to Specialty Drugs
August 17, 2023
The number of health plans that put in place restrictive policies that go beyond FDA-approved label is increasing, a new Tufts study finds.
FDA Approves First Drug for Rare Bone Disorder
FDA Approves First Drug for Rare Bone Disorder
FDA Approves First Drug for Rare Bone Disorder
August 17, 2023
Sohonos was approved to treat children with fibrodysplasia ossificans progressive, an ultra-rare disease that transforms the body’s soft tissue into bone. It has an annual list price of $624,000.
FDA Grants Priority Review for Tibsovo sNDA for Myelodysplastic Syndromes
FDA Grants Priority Review for Tibsovo sNDA for Myelodysplastic Syndromes
FDA Grants Priority Review for Tibsovo sNDA for Myelodysplastic Syndromes
August 16, 2023
Tibsovo is currently approved in the United States as a monotherapy to treat adults with IDH1-mutant relapsed or refractory acute myeloid leukemia.
New PBM Launches to Bring a New Model to Pharmacy Benefits
New PBM Launches to Bring a New Model to Pharmacy Benefits
New PBM Launches to Bring a New Model to Pharmacy Benefits
August 16, 2023
LucyRx has $500 million in equity it will use for acquisitions and to build technology and infrastructure. It aims to be a national, full-service alternative to the big three PBMs.
FDA Sets Review Date for Combination Antibiotic for Complicated UTIs
FDA Sets Review Date for Combination Antibiotic for Complicated UTIs
FDA Sets Review Date for Combination Antibiotic for Complicated UTIs
August 15, 2023
The FDA has granted priority review for cefepime-taniborbactam to treat patients with complicated urinary tract infections and set an action date of Feb. 22, 2024.
New Illinois Law Promotes PBM Transparency
New Illinois Law Promotes PBM Transparency
New Illinois Law Promotes PBM Transparency
August 15, 2023
Illinois Governor JB Pritzker signed into law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.
FDA Grants Accelerated Approval to Elrexfio for Multiple Myeloma
FDA Grants Accelerated Approval to Elrexfio for Multiple Myeloma
FDA Grants Accelerated Approval to Elrexfio for Multiple Myeloma
August 14, 2023
Elrexfio is a bispecific antibody to treat relapsed or refractory multiple myeloma. It will be available within the next few weeks and have a monthly list price of $41,500.
FDA Approves Long-Acting Botulinum Toxin for Cervical Dystonia
FDA Approves Long-Acting Botulinum Toxin for Cervical Dystonia
FDA Approves Long-Acting Botulinum Toxin for Cervical Dystonia
August 14, 2023
Daxxify is a long-acting botulinum toxin that will launch in 2024. It previously received FDA approval to treat frown lines.
FDA Approves Combination Tablet for Metastatic Prostate Cancer
FDA Approves Combination Tablet for Metastatic Prostate Cancer
FDA Approves Combination Tablet for Metastatic Prostate Cancer
August 14, 2023
The combination of niraparib and abiraterone in a single tablet — now with the name Akeega — will be available in mid-September and have a list price of $18,750 for a 30-day supply.
Kaiser Permanente Expects to Save $300 Million Switching to Amjevita
Kaiser Permanente Expects to Save $300 Million Switching to Amjevita
Kaiser Permanente Expects to Save $300 Million Switching to Amjevita
August 14, 2023
Kaiser Permanente has a 95% formulary compliance rate, and this allows the health plan to negotiate with pharmaceutical companies for lower prices.
What We’re Reading: Drug Prices May Lead to ACA Premium Increases; Dealing with Problem Doctors; Autism, Obesity and Other Co-Occurring Conditions
What We’re Reading: Drug Prices May Lead to ACA Premium Increases; Dealing with Problem Doctors; Autism, Obesity and Other Co-Occurring Conditions
What We’re Reading: Drug Prices May Lead to ACA Premium Increases; Dealing with Problem Doctors; Autism, Obesity and Other Co-Occurring Conditions
August 11, 2023
Fresenius Kabi Reaches Agreement with J&J over Stelara Biosimilar
Fresenius Kabi Reaches Agreement with J&J over Stelara Biosimilar
Fresenius Kabi Reaches Agreement with J&J over Stelara Biosimilar
August 11, 2023
Following similar agreements, the settlement allows Fresenius Kabi and Formycon to launch their ustekinumab biosimilar no later than April 15, 2025.
Study: Amjevita May Not Provide Much of a Discount
Study: Amjevita May Not Provide Much of a Discount
Study: Amjevita May Not Provide Much of a Discount
August 11, 2023
Biosimilars that are interchangeable with Humira could provide more competition on price, a new analysis suggests.
Tufts Evaluation Finds Health Plans Vary in Step Therapy for Camyzos
Tufts Evaluation Finds Health Plans Vary in Step Therapy for Camyzos
Tufts Evaluation Finds Health Plans Vary in Step Therapy for Camyzos
August 10, 2023
Payers’ requirements for the use of Camyzos in patients with obstructive hypertrophic cardiomyopathy are generally consistent with the registration study, but they also imposed restrictions beyond the FDA indication or ICER recommendation.
FDA Approves Talvey to Treat Blood Cancer
FDA Approves Talvey to Treat Blood Cancer
FDA Approves Talvey to Treat Blood Cancer
August 10, 2023
Talvey is a first-in-class bispecific antibody to treat adult patients with relapsed or refractory multiple myeloma. It will available in a few weeks and have a price of $45,000 per month.
FDA Issues Complete Response for Avasopasem for Severe Oral Mucositis
FDA Issues Complete Response for Avasopasem for Severe Oral Mucositis
FDA Issues Complete Response for Avasopasem for Severe Oral Mucositis
August 10, 2023
Avasopasem was under review to treat radiotherapy-induced severe oral mucositis in patients with head and neck cancer. The FDA has indicted that an additional trial would be needed to show safety and effectiveness of avasopasem.
Medicaid Coverage Increases for Pheburane for Urea Cycle Disorders
Medicaid Coverage Increases for Pheburane for Urea Cycle Disorders
Medicaid Coverage Increases for Pheburane for Urea Cycle Disorders
August 9, 2023
Current treatments urea cycle disorders, which causes ammonia to build up in the blood, have a bitter taste and smell. Pheburane was developed with a special coating that masks the taste of sodium phenylbutyrate. It has a list price of $4,375 per bottle.
Capital Blue Cross Saves by Accessing Manufacturer Coupons
Capital Blue Cross Saves by Accessing Manufacturer Coupons
Capital Blue Cross Saves by Accessing Manufacturer Coupons
August 9, 2023
Capital Blue Cross uses algorithms to help find drug manufacturer coupon programs. It has saved $4.5 million in the first quarter of 2023.
KFF Survey: Consumers Want Insurance to Pay for Weight Loss Drugs
KFF Survey: Consumers Want Insurance to Pay for Weight Loss Drugs
KFF Survey: Consumers Want Insurance to Pay for Weight Loss Drugs
August 8, 2023
Almost half of adults surveyed by KFF would be interested in taking a weight-loss drug, including many who say they only want to lose a little weight.
ASCO Abstract Highlights Growing Comfortability with Trastuzumab Biosimilars
ASCO Abstract Highlights Growing Comfortability with Trastuzumab Biosimilars
August 8, 2023
This abstract at the American Society of Clinical Oncology (ASCO 2023) looked at the growing utilization of trastuzumab biosimilars over time in India.
FDA Sets PDUFA Date for Monthly MS Drug
FDA Sets PDUFA Date for Monthly MS Drug
FDA Sets PDUFA Date for Monthly MS Drug
August 8, 2023
The FDA has assigned a March 8, 2024, action date for GA Depot, a once-monthly injection to treat patients with relapsing forms of multiple sclerosis.
<1
...
171819202122232425
...
229>
© 2025 MJH Life Sciences

All rights reserved.